<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398918</url>
  </required_header>
  <id_info>
    <org_study_id>H-25360</org_study_id>
    <nct_id>NCT00398918</nct_id>
  </id_info>
  <brief_title>Alcohol Self Administration Laboratory</brief_title>
  <official_title>Alcohol Self Administration Laboratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study in which our intent is to establish an alcohol administration
      laboratory in which we will be able to test the effect of the anticonvulsant medication
      zonisamide as compared to placebo on alcohol self administration and on cognitive functioning
      in non treatment seeking heavy users of alcohol. Our first goal is to establish the safety of
      zonisamide when used together with alcohol. Our second goal is to test the effect of an acute
      dose of zonisamide on alcohol consumption and show that it may reduce the consumption of
      alcohol. To achieve this goal we seek subjects with a history of heavy drinking to be tested
      on the self-administration procedures described below in two sessions with either zonisamide
      or placebo. These procedures will involve first, the administration of a challenge dose of
      ethanol to evaluate the effect of alcohol on performance on neuropsychological tests. This
      initial challenge will be followed by a period of alcohol self-administration in which the
      research subject can choose to select either ethanol or another reinforcer, money.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In preclinical studies three novel anticonvulsants have been studied. The administration of
      tiagabine did not decrease ethanol consumption in rodents (Schmitt et al., 2002; Rimondini et
      al., 2002). In a study with alcohol preferring mice topiramate reduced alcohol consumption in
      a two bottle choice prolonged access model of drinking (Gabriel and Cunningham, 2005). In a
      study done at our laboratory both topiramate and zonisamide were found to have similar
      effects on reducing the consumption of ethanol in Wistar rat (Knapp et al., 2004). More
      recently we found that zonisamide administration decreased alcohol consumption in a limited
      access model in the C57BL/B6 mouse. These results suggest that zonisamide might be useful as
      a medication for the treatment of alcohol dependence.

      Topiramate and zonisamide have some structural similarities with a sulfamate or
      methane-sulfonamide containing chain respectively attached to cyclic structure. These
      structural similarities may explain some of their pharmacological similarities including
      blockade of voltage sensitive sodium channels and low potency inhibition of carbonic
      anhydrase (Taverna et al., 1999; Dodgson et al., 2000; Schaf et al., 1987; Masudaet al.,
      1993). Both topiramate and zonisamide promote weight loss (McElroy et al., 2003; McElroy et
      al., 2004; Gadde et al., 2003). This effect may be a result of neuromodulation of the
      regulation of alcohol and food shared by these drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grams Ethanol Consumed During Second Hour of the Alcohol Self-Administration Sessions</measure>
    <time_frame>1 day</time_frame>
    <description>Grams Ethanol Consumed During Second Hour of the Alcohol Self-Administration Sessions for Zonisamide and Placebo Conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score Digit Symbol Modalities Test</measure>
    <time_frame>40 minutes post alcohol ingestion</time_frame>
    <description>Difference score between zonisamide and placebo treatment conditions for the Digit Symbol Modalities Test scores obtained 40 minutes after ingestion of a priming dose of ethanol.This test involves transcribing from a key in which numbers appear below a series of symbols to boxes below symbols matched to those in the key. This task must be completed in 90 nseconds. This test measures visuomotor speed and aspects of attention. Scoring is the total number of correctly transcribed numbers. The maximum score on this test 110 points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Zonisamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zonisamide</intervention_name>
    <description>zonisamide (100 mg)one time</description>
    <arm_group_label>Zonisamide</arm_group_label>
    <other_name>zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non treatment seeking subjects ages 21-55 must indicate no treatment for alcohol
             dependence in the preceding 6 months.

          2. Male subjects must drink no more than 40 standard drinks; female subjects no more than
             35 standard drinks a week as determined by the TLFB

          3. Subjects must be able to provide IC

          4. BAC must be 0.000 at the time of consent

          5. Female subjects of a child bearing potential must use an acceptable method of
             contraception which includes a barrier and spermicide, levonorgestrel implant,
             medroxyprogesterone, intrauterine progesterone contraceptive system or complete
             abstinence or surgical sterilization. Women who are using oral contraceptives must
             agree to an additional barrier method.

        Exclusion Criteria:

          1. Subject meeting DSM-IV-TR criteria for axis I diagnosis that require pharmacological
             treatment.

          2. Subject meeting substance dependence criteria for any substance other than alcohol or
             nicotine .

          3. Positive urine toxicology screen for opioids, cocaine, amphetamines, PCP, THC (may
             repeat THC if positive).

          4. History of severe alcohol withdrawals.

          5. Any medical or psychological condition that in the opinion of the investigator will
             preclude safe participation in the trial. These include a history of kidney stones in
             the past 10 years, significant liver disease with AST and ALT more than 3 times the
             normal range.

          6. Concomitant medications that will alter the pharmacodynamic/pharmacokinetic properties
             of the study medication. Participant who are taking the following medications:
             Amprenavir; Atazanavir; Clarithromycin; Delavirdine; Diclofenac; Fosamprenavir;
             Imatinib; Indinavir; Isoniazid; Itraconazole; Ketoconazole; Miconazole; Nefazodone;
             Nelfinavir; NiCARdipine; Propofol; Quinidine; Ritonavir; Telithromycin; Phenytoin;
             carbamazepine and phenobarbital

          7. Subjects on psychoactive medications must be on a stable dose more than 3 months

          8. Female subjects who are pregnant or nursing.

          9. Subject is facing future imprisonment.

         10. A known allergy to zonisamide or sulfa.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofra Sarid-Segal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Medical Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2006</study_first_submitted>
  <study_first_submitted_qc>November 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <results_first_submitted>February 8, 2010</results_first_submitted>
  <results_first_submitted_qc>April 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2010</results_first_posted>
  <last_update_submitted>June 17, 2017</last_update_submitted>
  <last_update_submitted_qc>June 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zonisamide-Placebo Sessions</title>
          <description>In this within subjects study, subjects received zonisamide in one session and placebo in a second</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zonisamide-Placebo Sessions</title>
          <description>In this within subjects study, subjects received zonisamide in one session and placebo in a second</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Grams Ethanol Consumed During Second Hour of the Alcohol Self-Administration Sessions</title>
        <description>Grams Ethanol Consumed During Second Hour of the Alcohol Self-Administration Sessions for Zonisamide and Placebo Conditions</description>
        <time_frame>1 day</time_frame>
        <population>This was a laboratory based study. An ITT analysis was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide-Placebo Sessions</title>
            <description>In this within subjects study, subjects received zonisamide in one session and placebo in a second</description>
          </group>
        </group_list>
        <measure>
          <title>Grams Ethanol Consumed During Second Hour of the Alcohol Self-Administration Sessions</title>
          <description>Grams Ethanol Consumed During Second Hour of the Alcohol Self-Administration Sessions for Zonisamide and Placebo Conditions</description>
          <population>This was a laboratory based study. An ITT analysis was used.</population>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Zonisamide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The analysis involved a within subjects comparison. The null hypothesis was that there would be no difference in the amount of ethanol consumed in either the first or second hour of self-administration sessions. Results presented here are for the second hour of the self-administration sessions.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Results presented are for post-hoc comparisons of least squares means with Tukey-Kramer adjucted p values.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>The estimated value is for the difference between the means obtained for the second hour of the self-administration sessions for the placebo and zonisamide conditions.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Digit Symbol Modalities Test</title>
        <description>Difference score between zonisamide and placebo treatment conditions for the Digit Symbol Modalities Test scores obtained 40 minutes after ingestion of a priming dose of ethanol.This test involves transcribing from a key in which numbers appear below a series of symbols to boxes below symbols matched to those in the key. This task must be completed in 90 nseconds. This test measures visuomotor speed and aspects of attention. Scoring is the total number of correctly transcribed numbers. The maximum score on this test 110 points.</description>
        <time_frame>40 minutes post alcohol ingestion</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Zonisamide-Placebo Sessions</title>
            <description>In this within subjects study, subjects received zonisamide in one session and placebo in a second</description>
          </group>
        </group_list>
        <measure>
          <title>Score Digit Symbol Modalities Test</title>
          <description>Difference score between zonisamide and placebo treatment conditions for the Digit Symbol Modalities Test scores obtained 40 minutes after ingestion of a priming dose of ethanol.This test involves transcribing from a key in which numbers appear below a series of symbols to boxes below symbols matched to those in the key. This task must be completed in 90 nseconds. This test measures visuomotor speed and aspects of attention. Scoring is the total number of correctly transcribed numbers. The maximum score on this test 110 points.</description>
          <population>ITT</population>
          <units>Numeric Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference in DSMT scores for zonisamide and placebo treatments 40 minutes after ingestion of ethanol.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>P value shown is for a post-hoc comparison of least squares means generated by the mixed model used.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>Analysis for difference between DSMT scores at 40 minutes post alcohol ingestion for zonisamide and placebo involved post-hoc comparisons of least squares means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zonisamide-Placebo Sessions</title>
          <description>In this within subjects study, subjects received zonisamide in one session and placebo in a second</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ofra Sarid-Segal, MD</name_or_title>
      <organization>Boston University</organization>
      <phone>617-414-1990</phone>
      <email>ofra.segal@bmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

